Home

Deck

Centene · CNC · NYSE

Centene is the largest U.S. government-sponsored managed-care insurer — 27.6M members across Medicaid, ACA Marketplace, Medicare Advantage, and stand-alone Medicare Part D — earning a thin spread between fixed premiums and members' medical costs.

$58.81
Price
$29B
Market cap
$194.8B
Revenue (FY25)
27.6M
Members (FY25-end)
Listed 2001 at split-adjusted $1.40; ran to $97 by mid-Aug 2022; lost over $11B of market cap on July 2, 2025 after CNC withdrew 2025 guidance the prior evening on a Marketplace acuity miss; back to $58.81 after the Q1 FY26 beat.
2 · The tension

A 350+ bp move in one ratio — Health Benefit Ratio — wiped $10.8B of operating income. The whole bull-bear case is whether it reverses.

  • The math. Every 100 bp of HBR is roughly $1.7B of pretax profit at FY25 scale. The cost-of-revenue ratio jumped from 78.8% in 2024 to 82.3% in 2025; operating income went from +$3.2B to –$7.6B while revenue still grew +19.4%.
  • Bull read — cyclical. Managed care prices 12–18 months ahead of the P&L. Q1 FY26 consolidated HBR was 87.3% and Medicaid HBR improved 50 bp YoY to 93.1%, 95% of the Ambetter Marketplace book has been repriced for 2026, and management raised FY26 adjusted EPS guide mid-cycle from >$3.00 to >$3.40.
  • Bear read — structural. Management's own FY26 consolidated HBR guide is 90.9–91.7% — it never returns to the pre-2025 87–88% band. The single hardest point one quarter of improvement cannot dismantle.
Q1 FY26 is one quarter of data. The Q2 print on July 28 is the next test — a re-spike of consolidated HBR above 90% with no rate catch-up flips the read from cyclical to structural.
3 · Where this disagrees with the Street

Consensus is anchored on a Hold and a ~$55 target. The variant: the repricing already happened — the print just hasn't caught up.

  • The Molina test. Molina, one-fourth the size, runs the same Medicaid + Marketplace + low-income Medicare mix — and printed +1.72% operating margin in FY25 versus CNC's –3.91%. That is the hard data point the "industry-wide structural break" thesis cannot explain.
  • The calendar disagreement. Medicaid composite rate yield is tracking ~4.5% for FY26; CMS 2027 MA rates landed at +2.48% versus a 0.09% proposal; 95% of Ambetter is repriced. The repricing has been done, but FY26 financials still reflect contracts struck on FY25 actuarial assumptions.
  • The conservative-reserve tell. Management explicitly stated it is "not reflecting the full suggested risk adjustment offset" on Marketplace in Q1. If the June 2026 Wakely refresh confirms a net receivable, segment margin lifts 100+ bp and the bear's "permanent morbidity" pillar collapses on a single datapoint.
Q1 FY26 adjusted EPS of $3.37 was well above pre-quarter consensus near $2.15 (a beat of roughly 57%). Even after the beat, the consensus rating sat at Hold — the market is still pricing for the repricing cycle to fail again.
4 · Money picture

The GAAP loss is goodwill ink. The cash engine ran straight through it.

$194.8B
FY25 Revenue +19.4% YoY
–$6.7B
FY25 GAAP Net Income incl. $6.7B goodwill impairment ($7.3B total impairments)
$5.1B
FY25 Operating Cash Flow through the loss year
$2.9B
Net Cash Position FY24 was $1.8B net debt

Goodwill compressed from $17.6B to $10.8B — non-cash. Free cash flow rebounded to $4.3B, $1B of senior notes was retired during Q1 FY26 (funded by a PDP-receivable sale), and period-end share count is down ~15% since 2020. The balance sheet earns the company time for the rate cycle to play out. The pressure point is the refinancing wall: $2.5B 4.25% notes par due Dec-2027 (~$1.2B outstanding after Q1 FY26 buyback) and $3.5B 4.625% notes par due Dec-2029, into sub-investment-grade spreads at S&P (BB+) and a Fitch BBB Negative outlook.

5 · Next 90 days

Three dated events will resolve more of the debate than the prior twelve months of speculation.

  • July 28, 2026 — Q2 FY26 earnings. The single most important print. Consolidated HBR sustained below 90% with Medicaid composite rate yield at or above the 4.5% guide validates the cyclical read; a re-spike above 91% with no rate catch-up confirms the structural reset.
  • June 2026 — Wakely Marketplace refresh. Independent actuary data on whether the 2025 Silver-to-Bronze migration concentrated permanent acuity, or whether 2026 repricing captured it. Determines whether Q1's partial risk-adjustment accrual flips to a full receivable.
  • October 2026 — CMS Star ratings + Q4 state Medicaid certifications for 2027. Decides whether the +2.48% MA rate tailwind translates to bonus dollars and whether OBBBA Medicaid work-requirement disenrollment gets state rate-offset language.
Multiple resolution signals fire inside 90 days. The signals that could refute — OBBBA rollout, 2027 state rate certifications — come 6–12 months later. The variant gets validated or refuted before the bear-case tails play out.
6 · Bull & Bear

Lean long, wait for confirmation — balance sheet removes tail risk, Q1 moved the right way, but one quarter is not the cycle.

  • For. $5.1B operating cash flow ran straight through a $6.7B GAAP loss; $1B of debt retired in Q1 FY26; debt-to-cap fell from 46.5% to 43.2% in one quarter; CEO Sarah London bought $490K of stock at $25.50 in Aug-2025.
  • For. Q1 FY26 Medicaid HBR improved 50 bp YoY to 93.1%, FY26 EPS guide raised mid-cycle to >$3.40, and Molina's profitable FY25 on the same business mix argues this was an execution gap, not a market break.
  • Against. Management's own FY26 consolidated HBR guide (90.9–91.7%) never returns to the pre-2025 78.8% cost-of-revenue ratio band. The bear's hardest point — and unresolved by a single quarter of improvement.
  • Against. Active securities class action (Lunstrum v. Centene, S.D.N.Y., No. 25-cv-05659), Feb-2026 House Judiciary subpoenas to eight ACA insurers (CNC included), sub-investment-grade credit at S&P (BB+). Director Wayne DeVeydt resigned from the CNC board on Aug 1, 2025 to become UnitedHealth's CFO.
Lean long with a hand on the exit. Two sequential quarters of consolidated HBR trending toward the high-80s with composite Medicaid rate growth at or above 4.5% flips this to full conviction. A re-spike of consolidated HBR above 91% in Q2 or Q3 flips it to avoid.

Watchlist to re-rate: Q2 FY26 consolidated and Medicaid HBR (July 28); June 2026 Wakely Marketplace data; 2027 state Medicaid rate certifications in CNC's top-five states.